Concurrent radiotherapy and tumor targeting with 111In-HMFG1-F(ab')2 in patients with MUC1-positive non-small cell lung cancer.

BACKGROUND: Combining external radiotherapy (XRT) and radioimmunotargeting might enhance tumor radiation without affecting morbidity, due to different toxicity profiles.

AIM: To assess 111In-F(ab')2-HMFG1 biodistribution, the influence of "low-dose" lysine on F(ab')2 renal uptake and provide data forfurther concurrent XRT and RIT.

PATIENTS AND METHODS: Twenty-three patients received injections of 111n-HMFG1-F(ab')2, with or without lysine co-infusion, 7 and 21 days after the initiation of XRT. Whole-body images, blood and urine activity were monitored.

RESULTS: Despite clear visualization of 111In-F(ab')2-HMFG1, the residence time and absorbed dose in tumors were low. The co-infusion of "low-dose" lysine did not reduce renal uptake, thus contradicting previously published results. The biodistribution differences after the first and the second injection might be attributed to human anti-mouse antibody (HAMA) response or Ag-complexation.

CONCLUSION: Low-dose lysine is not feasible. Larger amounts of lysine during extended infusion time are therefore advocated. It is proposed that repeated MAb injection be given during the first fractions of XRT.